

Dupixent® (dupilumab) – Expanded indication

- On June 7, 2022, <u>Sanofi</u> and <u>Regeneron</u> announced the <u>FDA approval</u> of <u>Dupixent (dupilumab)</u>, for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
 - Dupixent was previously approved for this indication in patients 6 years of age and older.
- Dupixent is also approved:
 - As an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma
 - As add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis
 - For the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis.
- The approval of Dupixent for the expanded indication was based on a randomized, double-blind, placebo-controlled study in 162 patients 6 months to 5 years of age, with moderate-to-severe atopic dermatitis. Patients received Dupixent plus topical corticosteroids or placebo plus topical corticosteroids. The primary endpoint was the proportion of patients with an Investigator's Global Assessment (IGA) 0 (clear) or 1 (almost clear) at week 16.
 - IGA 0 or 1 was achieved in 28% and 4% of patients who received Dupixent and placebo, respectively (treatment difference 24, 95% CI: 13, 34).
- The recommended dosage of Dupixent for pediatric patients 6 months to 5 years of age weighing 5 kg to less than 15 kg is 200 mg (one 200 mg injection) subcutaneously every 4 weeks. For pediatric patients 6 months to 5 years of age weighing 15 kg to less than 30 kg is 300 mg (one 300 mg injection) every 4 weeks.
 - Refer to the Dupixent drug label for dosing for all its other uses and indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.